Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | MLNR | O43193 | 7/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.42 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.42 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.42 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.42 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.42 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.42 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.42 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.42 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162032 | 0.98 | HTR2C (0.57) | HTR2CHTR2BHTR2AMLNRCYP2D6 | |
| Sulfuric Acid SCHEMBL174597 | 0.88 | MLNR (0.52) | HTR2CHTR2BHTR2AMLNRCYP2D6 | |
| Phosphoric Acid SCHEMBL174207 | 0.88 | HTR2C (0.47) | HTR2CHTR2BHTR2AMLNRCYP2D6 | |
| SCHEMBL174395 | 0.85 | MLNR (0.50) | HTR2CHTR2BHTR2AMLNRCYP2D6 | |
| Succinic Acid SCHEMBL174914 | 0.85 | HTR2C (0.45) | HTR2CHTR2BHTR2AMLNRCYP2D6 | |
| Glycolic Acid SCHEMBL174349 | 0.85 | HTR2C (0.45) | HTR2CHTR2BHTR2AMLNRCYP2D6 | |
| Malonic Acid SCHEMBL173339 | 0.85 | HTR2C (0.45) | HTR2CHTR2BHTR2AMLNRCYP2D6 | |
| Nitric Acid SCHEMBL174071 | 0.85 | MLNR (0.47) | HTR2CHTR2BHTR2AMLNRCYP2D6 | |
| SCHEMBL10773358 | 0.83 | ALDH1A1 (0.36) | HTR2CHTR2BHTR2AMLNRADRA2A | |
| Adipic Acid SCHEMBL173690 | 0.83 | HTR2C (0.42) | HTR2CHTR2BHTR2AMLNRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |